Grufity logoGrufity logo
ScreenerStocksFundsSectorsWatchlists
RARE

Ultragenyx Pharmaceutical Inc

RARE

41.42USD+0.31 (+0.75%)Market Closed
Watchlist

Market Summary

USD41.42+0.31
Market Closed
0.75%

RARE Alerts

  • Big jump in Earnings (Y/Y)
  • Losses in recent quarter

RARE Stock Price

View Fullscreen

RARE RSI Chart

RARE Valuation

Market Cap

3.0B

Price/Earnings (Trailing)

-4.67

Price/Sales (Trailing)

7.23

EV/EBITDA

-4.73

Price/Free Cashflow

-5.39

RARE Price/Sales (Trailing)

RARE Profitability

Operating Margin

91.02%

EBT Margin

-185.84%

Return on Equity

-326.14%

Return on Assets

-51.98%

Free Cashflow Yield

-18.57%

RARE Fundamentals

RARE Revenue

Revenue (TTM)

410.2M

Revenue Y/Y

8.1%

Revenue Q/Q

-9.47%

RARE Earnings

Earnings (TTM)

-635.3M

Earnings Y/Y

34.87%

Earnings Q/Q

0.11%

Price Action

Last 7 days

5.1%

Last 30 days

8.7%

Last 90 days

-0.1%

Trailing 12 Months

4.8%

How does RARE drawdown profile look like?

RARE Financial Health

Current Ratio

3.51

RARE Investor Care

Shares Dilution (1Y)

2.99%

Diluted EPS (TTM)

-8.98

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2023383.9M402.9M410.2M0
2022331.9M334.3M343.4M363.3M
2021334.1M359.4M359.6M351.4M
2020121.9M159.4M215.1M271.0M
201959.0M70.3M84.4M103.7M
201814.2M25.8M37.3M51.5M
2017752.8K1.4M2.0M2.6M
2016000133.0K
20150000
20140000
20130000

Latest Insider Trading transactions for RARE

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Oct 23, 2023
kassberg thomas richard
sold
-1,307,200
32.78
-39,878
cbo & evp
Oct 23, 2023
kassberg thomas richard
acquired
273,563
6.86
39,878
cbo & evp
Oct 19, 2023
kakkis emil d
sold
-1,604,030
33.52
-47,853
president & ceo
Oct 19, 2023
kakkis emil d
acquired
328,272
6.86
47,853
president & ceo
Oct 09, 2023
horn howard
acquired
-
-
80,366
chief financial officer
Sep 07, 2023
huizenga theodore alan
acquired
42,000
21.00
2,000
svp, chief accounting officer
Sep 07, 2023
huizenga theodore alan
sold
-88,249
40.7995
-2,163
svp, chief accounting officer
Sep 05, 2023
harris erik
sold
-227,760
37.96
-6,000
evp & chief commercial officer
Sep 01, 2023
huizenga theodore alan
sold
-36,032
37.1467
-970
svp, chief accounting officer
Jun 30, 2023
sanders corazon (corsee) d.
sold
-27,354
46.76
-585
-

1–10 of 50

Which funds bought or sold RARE recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Nov 24, 2023
DEUTSCHE BANK AG\
added
6.76
-7,164,380
33,786,600
0.02%
Nov 21, 2023
COMERICA BANK
reduced
-58.24
22,039
38,039
-%
Nov 21, 2023
Walleye Capital LLC
added
1,057
7,283,350
8,199,680
0.02%
Nov 21, 2023
Walleye Trading LLC
added
4,782
508,362
522,201
-%
Nov 17, 2023
JACOBS LEVY EQUITY MANAGEMENT, INC
added
23.83
-1,199,650
26,676,100
0.16%
Nov 15, 2023
JANE STREET GROUP, LLC
reduced
-61.8
-2,523,910
1,057,020
-%
Nov 15, 2023
CAPTRUST FINANCIAL ADVISORS
reduced
-6.17
-314,939
830,930
-%
Nov 15, 2023
Tudor Investment Corp Et Al
sold off
-100
-1,703,070
-
-%
Nov 15, 2023
Crestwood Advisors Group LLC
added
235
2,194,540
3,574,200
0.09%
Nov 15, 2023
PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO
reduced
-9.97
-430,000
982,000
-%

1–10 of 39

Latest Funds Activity

Are funds buying RARE calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own RARE
No. of Funds

Schedule 13G FIlings of Ultragenyx Pharmaceutical Inc

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Sep 11, 2023
vanguard group inc
10.12%
7,236,523
SC 13G/A
Feb 14, 2023
price t rowe associates inc /md/
5.8%
4,096,388
SC 13G/A
Feb 14, 2023
rtw investments, lp
5.7%
3,966,915
SC 13G
Feb 09, 2023
vanguard group inc
9.09%
6,374,230
SC 13G/A
Feb 06, 2023
wellington management group llp
7.42%
5,202,684
SC 13G
Feb 03, 2023
blackrock inc.
6.2%
4,336,492
SC 13G
Jan 10, 2023
federated hermes, inc.
4.41%
3,094,500
SC 13G/A
Mar 09, 2022
blackrock inc.
4.9%
3,411,414
SC 13G/A
Feb 14, 2022
federated hermes, inc.
5.85%
3,986,870
SC 13G/A
Feb 14, 2022
price t rowe associates inc /md/
16.9%
11,525,089
SC 13G/A

Recent SEC filings of Ultragenyx Pharmaceutical Inc

View All Filings
Date Filed Form Type Document
Nov 03, 2023
10-Q
Quarterly Report
Nov 02, 2023
8-K
Current Report
Oct 24, 2023
4
Insider Trading
Oct 23, 2023
8-K
Current Report
Oct 23, 2023
4
Insider Trading
Oct 23, 2023
144
Notice of Insider Sale Intent
Oct 20, 2023
424B5
Prospectus Filed
Oct 19, 2023
FWP
Prospectus Filed
Oct 19, 2023
144
Notice of Insider Sale Intent
Oct 17, 2023
424B5
Prospectus Filed

Peers (Alternatives to Ultragenyx Pharmaceutical Inc)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
31.4B
-
4.92% 426363.59%
-3.6K
218.4K
- -102.45%
30.7B
10.7B
11.84% -53.56%
-8.86
2.88
-53.67% -129.46%
22.0B
1.7B
4.71% -20.32%
-43.06
12.74
79.37% 56.87%
17.7B
2.3B
23.54% -7.88%
120.62
7.68
15.05% 75.21%
12.4B
3.6B
1.56% -32.86%
29.22
3.44
8.35% -51.49%
MID-CAP
7.5B
272.9M
38.55% 34.32%
-12.3
27.32
141.38% 4.43%
5.6B
-
16.25% 246.63%
-9.66
48.33
54.84% -12.96%
3.5B
631.9M
-10.80% 43.56%
-23.56
5.55
23.54% 31.53%
3.3B
223.4M
11.07% -7.88%
-16.26
14.69
- -26.24%
2.6B
240.7M
-11.66% -25.68%
-12.44
10.6
-1.03% -16.59%
SMALL-CAP
1.5B
348.4M
7.85% -14.88%
24.07
4.29
81.69% -7.29%
662.5M
1.0B
-19.01% -66.75%
-1.21
0.63
-43.15% 58.48%
100.5M
6.4M
-2.56% -78.77%
-0.61
15.6
-44.11% 50.48%
42.3M
-
410.00% -4.38%
-0.65
-
- -29.23%
26.3M
-
17.86% 4717.52%
-0.55
-
- -13.74%

Ultragenyx Pharmaceutical Inc News

Latest updates
Stocks Register07 Dec 202303:03 pm7 hours ago
MarketBeat06 Dec 202308:51 am37 hours ago
Defense World06 Dec 202308:51 am37 hours ago
MarketBeat05 Dec 202302:22 pm2 days ago
Nasdaq04 Dec 202310:06 pm3 days ago
Defense World28 Nov 202310:16 am9 days ago
Stocks Register20 Nov 202301:31 pm17 days ago
Yahoo Finance17 Nov 202308:00 am20 days ago
Stocks Register16 Nov 202301:02 pm21 days ago
Yahoo Finance14 Nov 202308:00 am23 days ago
Yahoo Finance04 Nov 202307:00 am33 days ago
Yahoo Finance04 Nov 202307:00 am33 days ago
Defense World03 Nov 202308:23 am34 days ago
Defense World26 Oct 202307:02 am42 days ago
Yahoo Finance25 Oct 202307:00 am43 days ago

Financials for Ultragenyx Pharmaceutical Inc

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Revenue-9.5%98,052,000108,309,000100,496,000103,348,00090,703,00089,343,00079,935,00083,389,00081,647,00086,975,00099,395,00091,542,00081,470,00061,709,00036,309,00035,593,00025,800,00024,149,00018,172,00016,261,00011,763,000
Cost Of Revenue10.8%10,987,0009,914,00012,257,0005,319,0008,631,0008,270,0006,100,0003,509,0004,175,0003,136,0005,188,0005,481,0002,348,0001,803,000-3,503,0005,107,0002,683,000766,000452,000507,000273,000
Operating Expenses----------169,751,000205,964,000187,623,000131,785,000124,764,000156,974,000130,045,000143,833,000136,623,000117,386,000106,601,000101,409,000
  S&GA Expenses-8.0%74,917,00081,403,00076,646,00072,849,00069,841,00068,137,00067,312,00059,431,00053,883,00053,410,00053,258,00051,042,00042,123,00042,252,00047,516,00041,877,00041,006,00039,812,00038,829,00034,476,00031,095,000
  R&D Expenses-4.7%157,245,000164,949,000165,698,000170,808,000237,297,000154,529,000143,155,000123,013,000113,417,000113,205,000147,518,000131,100,00087,314,00080,709,000112,961,00083,061,000100,144,00096,045,00078,105,00071,618,00070,041,000
EBITDA Margin----1.81-1.88-1.90-1.46-1.37-1.25-0.95-0.94-0.57-0.64-1.12-1.80-3.38-3.77-----
Income Taxes-11.2%650,000732,000495,000-1,451,0006,287,000302,000558,00020,000182,000463,000379,00070,000313,000415,000409,0002,561,000293,000213,000216,000126,000247,000
Earnings Before Taxes0.1%-158,999,000-159,096,000-163,477,000-153,284,000-238,819,000-157,860,000-151,762,000-122,438,000-72,816,000-121,965,000-135,762,000-23,941,000-68,532,00025,730,000-118,616,000-91,244,000-112,701,000-98,959,000-96,540,000-87,700,000-87,063,000
EBT Margin----1.86-1.93-1.95-1.51-1.41-1.29-0.99-0.97-0.61-0.68-1.17-1.86-3.46-3.85-----
Net Income0.1%-159,649,000-159,828,000-163,972,000-151,833,000-245,106,000-158,162,000-152,320,000-122,458,000-72,998,000-122,428,000-136,141,000-24,011,000-68,845,00025,315,000-119,025,000-93,805,000-112,994,000-99,172,000-96,756,000-87,826,000-87,310,000
Net Income Margin----1.87-1.95-1.97-1.51-1.42-1.29-0.99-0.98-0.61-0.69-1.19-1.89-3.49-3.88-----
Free Cashflow----181,901,000-117,312,000-121,391,000-108,180,000-149,705,000-70,392,000-80,209,000-85,427,000-175,760,000-84,398,000-65,747,00083,268,000-109,248,000-83,539,000-----
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets-5.6%1,2381,3111,3831,5451,6181,3211,3841,5221,4851,5121,5981,7601,2681,3141,2331,1358809591,008720765
  Current Assets-14.7%5997027668841,0136797088578479491,0711,295872906894851613699787522567
    Cash Equivalents-28.9%73.0010286.0013339216015430819829138471419733629843412313127011383.00
  Inventory12.5%32.0028.0027.0027.0022.0021.0018.0016.0015.0015.0012.0013.0014.0011.0011.0012.0014.0014.0011.007.006.00
  Net PPE2.7%29728927826023520717714111910588.0074.0049.0048.0048.0044.0032.0025.0022.0020.0020.00
  Goodwill0%44.0044.0044.0044.0044.0044.0044.0044.0044.0044.0044.0044.0044.0044.0044.0044.0044.0044.0044.0044.0044.00
Liabilities2.0%1,2061,1821,1631,1931,150643588600551540543605602618624482153139121111103
  Current Liabilities3.9%25424421826122722116718113612712719020122019710390.0075.0067.0075.0067.00
Shareholder's Equity-75.4%32.001292203524696787969239349721,0551,154666696609654727820887609663
  Retained Earnings-5.1%-3,264-3,104-2,944-2,781-2,629-2,384-2,225-2,073-1,951-1,878-1,755-1,619-1,595-1,526-1,552-1,433-1,339-1,226-1,127-1,030-942
  Additional Paid-In Capital1.9%3,2983,2373,1693,1403,1083,0713,0292,9972,8852,8502,8102,7732,2612,2212,1632,0872,0662,0462,0141,6401,605
Shares Outstanding1.0%72.0071.0071.0070.0070.0070.0070.0069.0068.0068.0067.0067.0060.0060.0058.0057.0058.0058.0053.0050.0050.00
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations-1.5%-117-116-156-90.34-95.34-77.26-117-54.34-59.65-65.36-159-62.45-61.9787.00-95.15-72.04-88.51-89.06-95.77-55.85-69.16
  Share Based Compensation----------------20.0020.0022.0020.0021.0021.00
Cashflow From Investing-35.3%64.0099.00111-171-16179.00-37.3669.00-40.76-41.25-18298.00-95.76-86.14-95.1267.0079.00-58.43-10174.0016.00
Cashflow From Financing-23.6%25.0033.00-0.722.004926.002.0086.008.0013.0013.0049019.0036.0056.003151.009.0035412.0025.00

RARE Income Statement

2023-09-30
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Revenues:    
Total revenues$ 98,052$ 90,703$ 306,857$ 259,981
Operating expenses:    
Cost of sales10,9878,63133,15823,001
Research and development157,245237,297487,892534,981
Selling, general and administrative74,91769,841232,966205,290
Total operating expenses243,149315,769754,016763,272
Loss from operations(145,097)(225,066)(447,159)(503,291)
Interest income5,8813,48318,1354,876
Change in fair value of equity investments(1,419)(1,626)(1,492)(21,139)
Non-cash interest expense on liabilities for sales of future royalties(17,665)(14,505)(48,676)(27,141)
Other expense(699)(1,105)(2,380)(1,746)
Loss before income taxes(158,999)(238,819)(481,572)(548,441)
Provision for income taxes(650)(6,287)(1,877)(7,147)
Net loss$ (159,649)$ (245,106)$ (483,449)$ (555,588)
Earnings per share, Basic$ (2.23)$ (3.5)$ (6.81)$ (7.96)
Earnings per share, Diluted$ (2.23)$ (3.5)$ (6.81)$ (7.96)
Weighted average number of shares outstanding, Basic71,664,49370,054,17370,987,80169,834,037
Weighted average number of shares outstanding, Diluted71,664,49370,054,17370,987,80169,834,037
Product sales    
Revenues:    
Total revenues$ 42,349$ 32,503$ 128,757$ 90,019
Royalty revenue    
Revenues:    
Total revenues55,7035,373106,91615,634
Collaboration and license    
Revenues:    
Total revenues$ 0$ 52,827$ 71,184$ 154,328

RARE Balance Sheet

2023-09-30
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 72,575$ 132,944
Marketable debt securities369,519614,818
Accounts receivable, net79,26340,445
Inventory31,80226,766
Prepaid expenses and other current assets46,02968,926
Total current assets599,188883,899
Property, plant, and equipment, net296,811259,726
Equity investments4,0395,531
Marketable debt securities82,071148,970
Right-of-use assets26,42725,961
Intangible assets, net157,302160,105
Goodwill44,40644,406
Other assets27,89616,846
Total assets1,238,1401,545,444
Current liabilities:  
Accounts payable33,35743,274
Accrued liabilities178,622204,678
Contract liabilities01,479
Lease liabilities12,06711,779
Liabilities for sales of future royalties29,9320
Total current liabilities253,978261,210
Lease liabilities34,55519,814
Deferred tax liabilities31,66731,667
Liabilities related to the sale of future royalties875,996875,439
Other liabilities10,2304,820
Total liabilities1,206,4261,192,950
Stockholders’ equity:  
Preferred stock -25,000,000 shares authorized; nil outstanding as of outstanding as of September 30, 2023 and December 31, 202200
Common stock - 250,000,000 shares authorized; 72,174,307 and 70,197,297 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively7270
Treasury stock, at cost, 8,444 and nil shares held as of September 30, 2023 and December 31, 2022, respectively(381)0
Deferred compensation obligation3810
Additional paid-in capital3,298,3573,140,019
Accumulated other comprehensive loss(2,244)(6,573)
Accumulated deficit(3,264,471)(2,781,022)
Total stockholders’ equity31,714352,494
Total liabilities and stockholders’ equity$ 1,238,140$ 1,545,444
RARE
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111 (ABO-102), an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.
 CEO
 WEBSITEwww.ultragenyx.com
 EMPLOYEES1311

Ultragenyx Pharmaceutical Inc Frequently Asked Questions


What is the ticker symbol for Ultragenyx Pharmaceutical Inc? What does RARE stand for in stocks?

RARE is the stock ticker symbol of Ultragenyx Pharmaceutical Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Ultragenyx Pharmaceutical Inc (RARE)?

As of Wed Dec 06 2023, market cap of Ultragenyx Pharmaceutical Inc is 2.97 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of RARE stock?

You can check RARE's fair value in chart. The fair value of Ultragenyx Pharmaceutical Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Ultragenyx Pharmaceutical Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for RARE so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Ultragenyx Pharmaceutical Inc a good stock to buy?

The fair value guage provides a quick view whether RARE is over valued or under valued. Whether Ultragenyx Pharmaceutical Inc is cheap or expensive depends on the assumptions which impact Ultragenyx Pharmaceutical Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RARE.

What is Ultragenyx Pharmaceutical Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 06 2023, RARE's PE ratio (Price to Earnings) is -4.67 and Price to Sales (PS) ratio is 7.23. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RARE PE ratio will change depending on the future growth rate expectations of investors.